Selective ERRβ/γ Ligands for Metabolic Disease Research
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack selective and effective ligands for modulating orphan nuclear receptors ERRβ and ERRγ, which are crucial for understanding and treating metabolic diseases like obesity and heart disease, as existing compounds are either non-selective or not useful experimentally due to potency issues with related receptors.
Innovation Solution
Development of synthetic compounds like DY131, DY159, DY162, DY163, and DY164, which are selectively activated by PGC-1α, acting as ERRα/β/γ agonists with minimal activity on ERα/β, facilitating cell-based reporter gene assays to demonstrate their efficacy and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to modulate orphan nuclear receptors ERRβ and ERRγ, then receptor modulation is achieved, but selectivity is lost due to activity on related estrogen receptors ERα/β
Solution Approach 1:
The patent applies local quality by introducing specific structural modifications at particular positions of the ligand molecule. Compound DY131 features a hydroxyl group at the 4-position of the benzoic acid ring and a diethylamino group at the 4-position of the benzylidene ring, which are strategically positioned to provide selective interaction with ERRβ/γ binding pockets while avoiding ERα/β activation. This localized structural differentiation enables selective receptor modulation.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters including the introduction of a hydroxyl group (changing functional group parameters), adjustment of the benzylidene hydrazide core structure (changing structural parameters), and modification of the amino group substitution pattern (changing chemical composition parameters). These parameter changes result in compounds with altered binding affinity and selectivity profiles, achieving preferential activation of ERRβ and ERRγ.
2Reliability
If existing compounds are used for ERRα/β/γ modulation, then some receptor activity is achieved, but experimental utility is reduced due to potency issues with related receptors
Solution Approach 1:
The patent applies the taking out principle by extracting and eliminating the problematic property of ERα/β activity from the compound profile. Compound DY131 is specifically designed to retain and enhance ERRβ/γ potency while removing or minimizing activity against ERα/β receptors. This selective extraction of desired activity from undesired activity provides compounds with high experimental utility for studying orphan nuclear receptors without confounding effects from estrogen receptor activation.
3Adaptability or versatility
If non-selective compounds are used to study orphan nuclear receptors, then broad receptor interaction is achieved, but specific biological activity understanding is hindered
Solution Approach 1:
The patent applies segmentation by dividing the receptor modulation function into selective segments. Instead of using compounds that broadly interact with multiple receptors, the invention creates compounds segmented to specifically target and activate ERRβ and ERRγ receptors. This segmentation is achieved through the DY131 molecular structure, which contains functional groups and structural features that selectively engage with ERRβ/γ binding sites, enabling precise measurement and understanding of specific orphan nuclear receptor biological activities.
Data Source
AI summary
Estrogen-Related Receptor (ERR) modulating compounds and methods for synthesis of said compounds are described.